BioMed X Appoints Former Max Planck Institute Head of Administration Nico Frisch as Vice President, Site Head Heidelberg

BioMed X Appoints Former Max Planck Institute Head of Administration Nico Frisch as Vice President, Site Head Heidelberg

• Nico Frisch brings strong administrative and operational experience from the Max Planck Institute for Medical Research to the BioMed X Heidelberg Institute.

HEIDELBERG, Germany, February 04, 2026 / Biotech Newswire / -- BioMed X, a leading innovation hub for pharma with headquarters in Heidelberg, today announced the appointment of Nico Frisch as Vice President, Site Head Heidelberg. In this role, Nico will oversee the administrative and operational management of the BioMed X Institute in Heidelberg and support the continued growth and professionalization of the organization’s research environment.

Nico Frisch is an administration and operations professional with hands-on experience in academic and research-driven environments. From 2022 to 2025, he served as Head of Administration at the Max Planck Institute for Medical Research in Heidelberg, where he was directly responsible for administrative operations, budgeting, and procurement. In this role, he worked closely with scientific leadership to ensure efficient, compliant, and future-oriented institutional operations.

He holds a Bachelor of Arts in Business Administration from DHBW Mosbach, Germany (2019) and a Master of Arts from IU International University (2022). Nico is currently pursuing a PhD in Organization and Management of Information Processes related to Economics at UNIBIT in Sofia, Bulgaria, in a remote program, in which he analyses the impact of government funded R&D of economic growth.

In his new role at BioMed X, Nico Frisch will be responsible for administrative strategy, operational excellence, and institutional governance at the Heidelberg site, supporting BioMed X’s mission to accelerate innovative biomedical research at the interface of academia and industry.

Nico Frisch, VP, Site Head Heidelberg, commented: “One of my key priorities in 2026 will be the planned move into our new facilities in Heidelberg. This relocation is the central operational project of the year and a decisive step in creating a centralized infrastructure that supports the scale, complexity, and interdisciplinary nature of our research moving forward. My focus is on ensuring a smooth transition and establishing an environment that enables our teams to collaborate efficiently and work with a long-term perspective.”

Nico Frisch

For high resolution please click the image.

Link to the press release

Semantic keywords: Leadership; Academies and Institutes; Biomedical Research; BioMed X; Nico Frisch; Site Head Heidelberg; BioMed X Institute; Heidelberg; administrative strategy; operational excellence; management; institutional governance; biomedical research; Max Planck Institute for Medical Research; Head of Administration; administrative operations

About BioMed X
BioMed X is a leading innovation hub for pharma. With our global network of research institutes at top universities and incubators within pharmaceutical companies, we bridge the gap between academia and industry. We are pioneers in applying the principles of design thinking and crowdsourcing to drug discovery and development. With our unique model, we identify key challenges across all therapeutic areas, recruit top academic talent, and co-create tailored solutions with our pharma partners. In our stimulating ecosystem, early-career researchers grow into future scientific leaders. They perform exploratory research, deliver industry-grade results, and pave the way to next-generation therapies. At BioMed X, we value curiosity, diversity, and purpose. Our goal is to serve as a vital catalyst for innovation in global health for the benefit of all patients.